Prevalence and clinical relevance of tumor-associated tissue eosinophilia (TATE) in breast cancer
Copyright © 2020 Elsevier Inc. All rights reserved..
BACKGROUND: Tumor-associated tissue eosinophilia (TATE) has been associated with outcomes in a variety of solid tumors; however, its role in breast cancer is not well defined. We hypothesized that tumor-associated tissue eosinophilia is associated with a high mutation and neoantigen load, and we assessed its correlation with cancer outcomes.
METHODS: The Cancer Genome Atlas was analyzed for eosinophil signatures in breast cancer specimens. Descriptive analyses were performed, including the tumor-infiltrating cell composition using CIBERSORT, cytolytic activity score, and gene set enrichment analysis. Overall survival and disease-free survival were calculated using the Kaplan-Meier method.
RESULTS: Out of 1069 cases analyzed, 40 (3.7%) had tissue eosinophils (the tumor-associated tissue eosinophilia group). Tumor-associated tissue eosinophilia was noted in 32.5% luminal, 5% HER2-positive, and 15% triple-negative breast cancer subtypes. The single nucleotide variant-neoantigen load was significantly higher in the tumor-associated tissue eosinophilia group (P = .005), with a higher nonsilent mutation rate (P = .01). The tumor-associated tissue eosinophilia group had lower cytolytic activity (P = .02) but had enriched MYC-targeted (P = .002), E2F-targeted (P = .04), deoxyribonucleic acid repair (P = .03), and unfolded protein response gene sets (P = .05). Tumor-associated tissue eosinophilia was associated with a trend toward improved disease-free survival (P = .06) but presented no differences in overall survival (P = .56).
CONCLUSION: Tumor-associated tissue eosinophilia was noted in 3.7% of breast cancers and was associated with a higher single nucleotide variant-neoantigen load and nonsilent mutation rate, similar to that of tumor-infiltrating lymphocytes in the triple-negative subtype. However, a lower cytolytic activity score and enriched cell proliferation-related gene sets implicate different roles for tumor-associated tissue eosinophilia than for tumor-infiltrating lymphocytes.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:169 |
---|---|
Enthalten in: |
Surgery - 169(2021), 5 vom: 27. Mai, Seite 1234-1239 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chouliaras, Konstantinos [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 26.07.2021 Date Revised 03.05.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.surg.2020.07.052 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM315295236 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM315295236 | ||
003 | DE-627 | ||
005 | 20231225154611.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.surg.2020.07.052 |2 doi | |
028 | 5 | 2 | |a pubmed24n1050.xml |
035 | |a (DE-627)NLM315295236 | ||
035 | |a (NLM)32958266 | ||
035 | |a (PII)S0039-6060(20)30525-0 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chouliaras, Konstantinos |e verfasserin |4 aut | |
245 | 1 | 0 | |a Prevalence and clinical relevance of tumor-associated tissue eosinophilia (TATE) in breast cancer |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.07.2021 | ||
500 | |a Date Revised 03.05.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
520 | |a BACKGROUND: Tumor-associated tissue eosinophilia (TATE) has been associated with outcomes in a variety of solid tumors; however, its role in breast cancer is not well defined. We hypothesized that tumor-associated tissue eosinophilia is associated with a high mutation and neoantigen load, and we assessed its correlation with cancer outcomes | ||
520 | |a METHODS: The Cancer Genome Atlas was analyzed for eosinophil signatures in breast cancer specimens. Descriptive analyses were performed, including the tumor-infiltrating cell composition using CIBERSORT, cytolytic activity score, and gene set enrichment analysis. Overall survival and disease-free survival were calculated using the Kaplan-Meier method | ||
520 | |a RESULTS: Out of 1069 cases analyzed, 40 (3.7%) had tissue eosinophils (the tumor-associated tissue eosinophilia group). Tumor-associated tissue eosinophilia was noted in 32.5% luminal, 5% HER2-positive, and 15% triple-negative breast cancer subtypes. The single nucleotide variant-neoantigen load was significantly higher in the tumor-associated tissue eosinophilia group (P = .005), with a higher nonsilent mutation rate (P = .01). The tumor-associated tissue eosinophilia group had lower cytolytic activity (P = .02) but had enriched MYC-targeted (P = .002), E2F-targeted (P = .04), deoxyribonucleic acid repair (P = .03), and unfolded protein response gene sets (P = .05). Tumor-associated tissue eosinophilia was associated with a trend toward improved disease-free survival (P = .06) but presented no differences in overall survival (P = .56) | ||
520 | |a CONCLUSION: Tumor-associated tissue eosinophilia was noted in 3.7% of breast cancers and was associated with a higher single nucleotide variant-neoantigen load and nonsilent mutation rate, similar to that of tumor-infiltrating lymphocytes in the triple-negative subtype. However, a lower cytolytic activity score and enriched cell proliferation-related gene sets implicate different roles for tumor-associated tissue eosinophilia than for tumor-infiltrating lymphocytes | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
700 | 1 | |a Tokumaru, Yoshihisa |e verfasserin |4 aut | |
700 | 1 | |a Asaoka, Mariko |e verfasserin |4 aut | |
700 | 1 | |a Oshi, Masanori |e verfasserin |4 aut | |
700 | 1 | |a Attwood, Kristopher M |e verfasserin |4 aut | |
700 | 1 | |a Yoshida, Kazuhiro |e verfasserin |4 aut | |
700 | 1 | |a Ishikawa, Takashi |e verfasserin |4 aut | |
700 | 1 | |a Takabe, Kazuaki |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Surgery |d 1945 |g 169(2021), 5 vom: 27. Mai, Seite 1234-1239 |w (DE-627)NLM000023590 |x 1532-7361 |7 nnns |
773 | 1 | 8 | |g volume:169 |g year:2021 |g number:5 |g day:27 |g month:05 |g pages:1234-1239 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.surg.2020.07.052 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 169 |j 2021 |e 5 |b 27 |c 05 |h 1234-1239 |